Akari Therapeutics appoints Vatnak Vat-Ho chief business officer
AKTX•Akari Therapeutics named Vatnak Vat-Ho chief business officer, responsible for corporate strategy, partnering, licensing and investor engagement. The company said he has more than 20 years of experience and has worked on deals totaling $25 billion.
1. Executive appointment
Akari Therapeutics named Vatnak Vat-Ho chief business officer to lead corporate strategy, partnering, licensing and investor engagement. He brings more than 20 years of experience in oncology business development, biopharma strategy, equity research and healthcare investing, and has worked on deals totaling $25 billion.
2. Prior experience
Vat-Ho most recently served as chief business officer at Ryvu Therapeutics, where he closed an ADC payload collaboration with Exelixis and originated a multi-target immuno-oncology research collaboration with BioNTech. Akari is advancing its TROP2-targeted ADC AKTX-101 toward the clinic alongside its PH1 payload platform.
